Citation: | Liu Zhaobo, Wu Jushan, Lin Dongdong, et al. Safety of PD-1 inhibitor in preoperative treatment of liver transplantation for liver cancer[J]. ORGAN TRANSPLANTATION, 2021, 12(4): 445-449. doi: 10.3969/j.issn.1674-7445.2021.04.011 |
[1] |
张笑晨, 胡玉琳. 晚期肝细胞癌患者PD-1阻断期间的疾病超进展[J]. 临床肝胆病杂志, 2020, 36(11): 2578. https://www.cnki.com.cn/Article/CJFDTOTAL-LCGD202011053.htm
ZHANG XC, HU YL. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma[J]. J Clin Hepatol, 2020, 36(11): 2578. https://www.cnki.com.cn/Article/CJFDTOTAL-LCGD202011053.htm
|
[2] |
XU C, CHEN YP, DU XJ, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network Meta-analysis[J]. BMJ, 2018, 363: k4226. DOI: 10.1136/bmj.k4226.
|
[3] |
MUNKER S, DE TONI EN. Use of checkpoint inhibitors in liver transplant recipients[J]. United European Gastroenterol J, 2018, 6(7): 970-973. DOI: 10.1177/2050640618774631.
|
[4] |
KUMAR V, SHINAGARE AB, RENNKE HG, et al. The safety and efficacy of checkpoint inhibitors in transplant recipients: a case series and systematic review of literature[J]. Oncologist, 2020, 25(6): 505-514. DOI: 10.1634/theoncologist.2019-0659.
|
[5] |
宾阳阳, 李杰群, 李强, 等. PD-1单克隆抗体治疗实体器官移植术后恶性肿瘤的系统评价[J]. 器官移植, 2020, 11(3): 384-390. DOI: 10.3969/j.issn.1674-7445.2020.03.011.
BIN YY, LI JQ, LI Q, et al. Systematic evaluation on PD-1 monoclonal antibody in the treatment of malignant tumor after solid organ transplantation[J]. Organ Transplant, 2020, 11(3): 384-390. DOI: 10.3969/j.issn.1674-7445.2020.03.011.
|
[6] |
SCHWACHA-EIPPER B, MINCIUNA I, BANZ V, et al. Immunotherapy as a downstaging therapy for liver transplantation[J]. Hepatology, 2020, 72(4): 1488-1490. DOI: 10.1002/hep.31234.
|
[7] |
NORDNESS MF, HAMEL S, GODFREY CM, et al. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient?[J]. Am J Transplant, 2020, 20(3): 879-883. DOI: 10.1111/ajt.15617.
|
[8] |
JOHNSON DB, CHANDRA S, SOSMAN JA. Immune checkpoint inhibitor toxicity in 2018[J]. JAMA, 2018, 320(16): 1702-1703. DOI: 10.1001/jama.2018.13995.
|
[9] |
POSTOW MA, SIDLOW R, HELLMANN MD. Immune-related adverse events associated with immune checkpoint blockade[J]. N Engl J Med, 2018, 378(2): 158-168. DOI: 10.1056/NEJMra1703481.
|
[10] |
RIELLA LV, WATANABE T, SAGE PT, et al. Essential role of PDL1 expression on nonhematopoietic donor cells in acquired tolerance to vascularized cardiac allografts[J]. Am J Transplant, 2011, 11(4): 832-840. DOI: 10.1111/j.1600-6143.2011.03451.x.
|
[11] |
TANAKA K, ALBIN MJ, YUAN X, et al. PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection[J]. J Immunol, 2007, 179(8): 5204-5210. DOI: 10.4049/jimmunol.179.8.5204.
|
[12] |
SHI XL, MANCHAM S, HANSEN BE, et al. Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction[J]. J Hepatol, 2016, 64(6): 1274-1282. DOI: 10.1016/j.jhep.2016.02.034.
|
[13] |
MORITA M, FUJINO M, JIANG G, et al. PD-1/B7-H1 interaction contribute to the spontaneous acceptance of mouse liver allograft[J]. Am J Transplant, 2010, 10(1): 40-46. DOI: 10.1111/j.1600-6143.2009.02859.x.
|
[14] |
RIELLA LV, PATERSON AM, SHARPE AH, et al. Role of the PD-1 pathway in the immune response[J]. Am J Transplant, 2012, 12(10): 2575-2587. DOI: 10.1111/j.1600-6143.2012.04224.x.
|
[15] |
ONO Y, PEREZ-GUTIERREZ A, NAKAO T, et al. Graft-infiltrating PD-L1hi cross-dressed dendritic cells regulate antidonor T cell responses in mouse liver transplant tolerance[J]. Hepatology, 2018, 67(4): 1499-1515. DOI: 10.1002/hep.29529.
|
[16] |
RAMIREZ CB, MARINO IR. The role of basiliximab induction therapy in organ transplantation[J]. Expert Opin Biol Ther, 2007, 7(1): 137-148. DOI: 10.1517/14712598.7.1.137.
|
[17] |
HAMMERS HJ, PLIMACK ER, INFANTE JR, et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study[J]. J Clin Oncol, 2017, 35(34): 3851-3858. DOI: 10.1200/JCO.2016.72.1985.
|
[18] |
ZHANG JC, CHEN WD, ALVAREZ JB, et al. Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity[J]. Acta Pharmacol Sin, 2018, 39(11): 1693-1698. DOI: 10.1038/s41401-018-0062-2.
|
[19] |
MOSLEHI JJ, SALEM JE, SOSMAN JA, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis[J]. Lancet, 2018, 391(10124): 933. DOI: 10.1016/S0140-6736(18)30533-6.
|
[20] |
MAHMOOD SS, FRADLEY MG, COHEN JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors[J]. J Am Coll Cardiol, 2018, 71(16): 1755-1764. DOI: 10.1016/j.jacc.2018.02.037.
|
[21] |
ESCUDIER M, CAUTELA J, MALISSEN N, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity[J]. Circulation, 2017, 136(21): 2085-2087. DOI: 10.1161/CIRCULATIONAHA.117.030571.
|
[22] |
HARDY T, YIN M, CHAVEZ JA, et al. Acute fatal myocarditis after a single dose of anti-PD-1 immunotherapy, autopsy findings: a case report[J]. Cardiovasc Pathol, 2020, 46: 107202. DOI: 10.1016/j.carpath.2020.107202.
|
[23] |
WANG F, SUN X, QIN S, et al. A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China[J]. Chin Clin Oncol, 2020, 9(2): 16. DOI: 10.21037/cco.2020.03.08.
|
[24] |
BURLA J, BLUEMEL S, BIEDERMANN L, et al. Retrospective analysis of treatment and complications of immune checkpoint inhibitor-associated colitis: histological ulcerations as potential predictor for a steroid-refractory disease course[J]. Inflamm Intest Dis, 2020, 5(3): 109-116. DOI: 10.1159/000507579.
|
[25] |
WANG DY, SALEM JE, COHEN JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and Meta-analysis[J]. JAMA Oncol, 2018, 4(12): 1721-1728. DOI: 10.1001/jamaoncol.2018.3923.
|
[26] |
SALEM JE, MANOUCHEHRI A, MOEY M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study[J]. Lancet Oncol, 2018, 19(12): 1579-1589. DOI: 10.1016/S1470-2045(18)30608-9.
|
[27] |
WINER A, BODOR JN, BORGHAEI H. Identifying and managing the adverse effects of immune checkpoint blockade[J]. J Thorac Dis, 2018, 10(Suppl 3): S480-S489. DOI: 10.21037/jtd.2018.01.111.
|